Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/139309PSEUDOMONAS INACTIVATED VACCINE "PSEUDOPRIMAVAC" AGAINST PSEUDOMONAS
WO 02.07.2020
Int.Class A61K 35/74
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
Appl.No PCT/UA2019/000163 Applicant MARKOV, Ihor Semenovych Inventor MARKOV, Ihor Semenovych
The inventions relate to medical microbiology and the pharmaceutical industry, in particular to vaccine preparations, namely vaccines against Pseudomonas infection, methods for the production of said vaccines, and methods of treatment and prophylaxis, and can be used for therapeutic and prophylactic purposes in acute and chronic bacterial diseases of Pseudomonas etiology. A vaccine comprises at least 12 clinical pathogenic strains of four types of bacteria of genus Pseudomonas, namely: 9 of Pseudomonas aeruginosa, 1 of Pseudomonas maltophilia, 1 of Pseudomonas alcaligenes and 1 of Pseudomonas stutzeri, isolated in various acute and chronic inflammatory diseases of bacterial etiology. The inventions increase the immunogenic effect of the vaccine, strengthen the immunological and clinical effect after vaccination without allergic reactions and provide a wide spectrum of application.
2.WO/2020/139852COMBINATIONS OF ENGINEERED ANTIMICROBIAL PROBIOTICS FOR TREATMENT OF GASTROINTESTINAL TRACT PATHOGENS
WO 02.07.2020
Int.Class A61K 35/741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
Appl.No PCT/US2019/068400 Applicant GENERAL PROBIOTICS, INC. Inventor KAZNESSIS, Yiannis John
Embodiments herein relate to engineered antimicrobial probiotics for the treatment of gastrointestinal tract pathogens. In an embodiment, a composition for treatment of an animal is included. The composition can include a first genetically engineered bacterium comprising a first exogenous polynucleotide. The first exogenous polynucleotide can include a first heterologous promoter and a first polynucleotide that encodes a first antimicrobial protein. The composition can also include a second genetically engineered bacterium comprising a second exogenous polynucleotide. The second exogenous polynucleotide can include a second heterologous promoter and a second polynucleotide that encodes a second antimicrobial protein. The first heterologous promoter can be induced by one set of exogenous environmental conditions found in the gastrointestinal tract of the animal and the second heterologous promoter can be induced by a second set of exogenous environmental conditions found in the gastrointestinal tract of the animal. Other embodiments are also included herein.
3.WO/2020/139873TOLLIP DEFICIENT NEUTROPHILS AND USES THEREOF
WO 02.07.2020
Int.Class A61K 35/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Appl.No PCT/US2019/068443 Applicant VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY Inventor LI, Liwu
Described herein are modified cells and compositions thereof, wherein the cells can have reduced or eliminated Tollip gene and/or protein expression. In some embodiments, the modified cells can be neutrophils. Also described herein are methods of making and using the modified cells and compositions thereof. In some embodiments, the modified cells having reduced or eliminated Tollip gene and/or protein expression can be administered to a subject in need thereof.
4.WO/2020/133436METHOD AND CULTURE MEDIUM FOR INDUCING EMBRYONIC STEM CELL TO DIFFERENTIATE INTO ENDOMETRIAL GLANDULAR EPITHELIAL PRECURSOR CELL
WO 02.07.2020
Int.Class C12N 5/0735
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
073Embryonic cells or tissues; Foetal cells or tissues
0735Embryonic stem cells; Embryonic germ cells
Appl.No PCT/CN2018/125685 Applicant JIANG, Xiuxiu Inventor JIANG, Xiuxiu
Disclosed are a method and a culture medium for inducing a human embryonic stem cell to differentiate into an endometrial glandular epithelial precursor cell. The method comprises culturing an epithelial cell formed from induced proliferation of a human embryonic stem cell in a differentiation culture medium for an endometrial glandular epithelial precursor cell to induce the epithelial cell to differentiate into the endometrial glandular epithelial precursor cell, the differentiation culture medium for an endometrial glandular epithelial precursor cell comprising EGF, FBS, GlutaMAX and WNT3A. The method can induce a human embryonic stem cell to differentiate into an endometrial glandular epithelial precursor cell. The method is simple to operate and can produce, from a single embryonic stem cell clone, endometrial glandular epithelial precursor cells at high yield in the order of millions of cells and with a high purity of nearly 100%. The endometrial glandular epithelial precursor cells obtained from the method can be used for treating diseases associated with absence of endometrium, difficulty in endometrial hyperplasia, intrauterine adhesions, and early uterine abortion, among others.
5.WO/2020/138510ACQUISITION OF L1CAM-POSITIVE CELLS FROM CEREBRAL CORTEX CELLS AND USE THEREOF AS CELL PREPARATION
WO 02.07.2020
Int.Class A61P 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
Appl.No PCT/JP2019/051652 Applicant KYOTO UNIVERSITY Inventor TAKAHASHI, Jun
This application provides: a method that is for acquiring L1CAM-positive cells and that comprises isolating and collecting L1CAM-positive cells from cerebral cortex cells derived from a mammal, such as human, using the cell surface marker L1CAM as an indicator; L1CAM-positive cells obtained using the method; a cell preparation that contains these cells and that is for treating a cerebral cortex disorder and/or a cerebral cortex spinal tract disorder; and a method that is for treating a cerebral cortex disorder and/or a cerebral cortex spinal tract disorder and that comprises administering a cell preparation to the cerebral cortex and/or cerebral cortex spinal tract of a subject having a cerebral cortex disorder and/or a cerebral cortex spinal tract disorder.
6.WO/2020/139874CHEMICALLY PROGRAMMED NEUTROPHILS AND USES THEREOF
WO 02.07.2020
Int.Class A61K 35/15
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
Appl.No PCT/US2019/068448 Applicant VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY Inventor LI, Liwu
Described herein are embodiments of chemically modified neutrophils and pharmaceutical formulations thereof. Also described herein are 4-phenylbutyrate pharmaceutical formulations. Also described herein are methods of chemically modifying neutrophils. Also described herein are treatments for non-resolving inflammation and/or related diseases or conditions, including but not limited to atherosclerosis, cardiovascular disease, stroke, myocardial infarction, neurological disease, and/or a symptom thereof in a subject in need thereof.
7.WO/2020/140012LYOPHILIZED VIRUS FORMULATIONS
WO 02.07.2020
Int.Class A61K 9/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
19lyophilised
Appl.No PCT/US2019/068700 Applicant AMGEN INC. Inventor FLOOD, Enrique, Alexander
Provided herein is a powder comprising a live, attenuated virus, recombinant human serum albumin (rHSA), a sugar other than lactose, a sugar alcohol, a source of phosphate, a source of chloride, wherein the composition is substantially free of lactose, gelatin, antibiotic, and free amino acids. In exemplary aspects, the powder is a lyophilizate of a liquid composition. Related liquid compositions, methods of preparing an oncolytic virus for administration and methods of treating melanoma are also provided herein.
8.WO/2020/136301HOLDEMANELLA SP. BACTERIUM AND USE THEREOF
WO 02.07.2020
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No PCT/ES2019/070882 Applicant CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) Inventor SANZ HERRANZ, Yolanda
The present invention relates to the strain Holdemanella biformis, the strain H. biformis CECT 9752, its cellular components, metabolites and secreted molecules, and to compositions comprising the aforementioned products, in addition to the use of said strain, but also of the genus Holdemanella, and to the species H. biformis for preventing alterations in energy homeostasis and glucose metabolism, including, inter alia, glucose intolerance, insulin resistance, metabolic syndrome and diabetes.
9.WO/2020/138028CELL TRANSPLANT KIT, METHOD FOR MANUFACTURING BAG-LIKE STRUCTURE, AND THERAPEUTIC AGENT FOR DIABETES
WO 02.07.2020
Int.Class A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
Appl.No PCT/JP2019/050494 Applicant FUJIFILM CORPORATION Inventor KOGAWA Ryo
The purpose of the present invention is to provide: a cell transplant kit that can exhibit a high therapeutic effect by transplanted cells; a method for manufacturing a bag-like structure used in the cell transplant kit; and a therapeutic agent for diabetes comprising the cell transplant kit. According to the present invention, there is provided a cell transplant kit comprising: a first bag-like structure composed of a membrane having holes with an average hole diameter of 0.2 mm or less; and a plurality of second bag-like structures having an average major axis larger than the average hole diameter of the holes of the first bag-like structure, wherein at least some of the plurality of second bag-like structures contain cells. According to the present invention, there is provided a method for manufacturing a bag-like structure used in the cell transplant kit. According to the present invention, there is provided a therapeutic agent for diabetes comprising the cell transplant kit.
10.WO/2020/139311"ECOPRIMAVAC" ESCERICHIA- AND ENTEROCOCCUS-BASED INACTIVATED LIQUID VACCINE AGAINST E. COLI AND ENTEROCOCCI, METHOD FOR PRODUCTION THEREOF, AND METHOD OF TREATMENT AND PROPHYLAXIS USING SAME
WO 02.07.2020
Int.Class A61K 35/74
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
Appl.No PCT/UA2019/000165 Applicant MARKOV, Ihor Semenovych Inventor MARKOV, Ihor Semenovych
The group of inventions relates to medical microbiology and the pharmaceutical industry, and more particularly to vaccine preparations, and even more particularly to vaccines against intestinal enterobacteriaceae and enterococci, methods for production thereof and methods of treatment and prophylaxis of localised and systemic, acute and chronic diseases of bacterial aetiology in children and adults. The EcoPrimavac Escerichia- and Enterococcus-based inactivated liquid vaccine against E. coli and Enterococcus comprises Escherichia coli, Enterococcus faecalis, Enterococcus faecium and Enterococcus durans bacterial strains, with no less than 22 bacterial strains in total, and more particularly: Escherichia coli - 9, Enterococcus faecalis - 8, Enterococcus faecium - 3, Enterococcus durans - 2 from specific locations, isolated from various acute and chronic inflammatory diseases of bacterial aetiology in children and adults, which have various degrees of antibiotic resistance and include hospital strains having 100% antibiotic resistance, inter alia, bacterial strains deposited at the Depository of the Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine.